CD79A and nasopharyngeal carcinoma: Epstein-Barr virus (EBV) deoxyribonucleic acid (DNA) levels (8), along with virus capsid antigen-immunoglobulin A (VCA-IgA) and early antigen-immunoglobulin A (EA-IgA) antibodies, are widely recognized as key biomarkers for NPC risk assessment, offering a noninvasive approach to early detection (10, 16).